AWM
VRTX icon

Angeles Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Angeles Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$614K Buy
1,376
+208
+18% +$97K 0.03% 198
2025
Q4 		$530K Buy
1,168
+164
+16% +$70.7K 0.03% 202
2025
Q3 		$393K Sell
1,004
-280
-22% -$117K 0.02% 217
2025
Q2 		$572K Buy
1,284
+29
+2% +$13.4K 0.04% 171
2025
Q1 		$608K Buy
1,255
+208
+20% +$96.9K 0.05% 127
2024
Q4 		$422K Sell
1,047
-67
-6% -$31.1K 0.03% 159
2024
Q3 		$518K Sell
1,114
-8
-0.7% -$3.84K 0.04% 132
2024
Q2 		$526K Buy
1,122
+55
+5% +$23.9K 0.05% 124
2024
Q1 		$446K Buy
1,067
+230
+27% +$97.2K 0.04% 126
2023
Q4 		$341K Buy
837
+3
+0.4% +$1.11K 0.04% 139
2023
Q3 		$290K Sell
834
-30
-3% -$10.5K 0.04% 135
2023
Q2 		$304K Buy
864
+46
+6% +$15.5K 0.04% 139
2023
Q1 		$258K Sell
818
-192
-19% -$57.6K 0.04% 147
2022
Q4 		$292K Buy
1,010
+231
+30% +$70.4K 0.05% 130
2022
Q3 		$226K Buy
+779
New +$224K 0.04% 141

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Angeles Wealth Management's VRTX Position: Q1 2026 in Review

Angeles Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 18% in Q1 2026, buying an estimated $97K and bringing the position to 1,376 shares worth $614K. The position accounts for 0.03% of the portfolio, ranked #198.

Angeles Wealth Management first reported a position in VRTX in Q3 2022 and has held it in 15 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Angeles Wealth Management held 1,376 shares of Vertex Pharmaceuticals worth $614K as of Q1 2026.
  • Angeles Wealth Management bought 208 Vertex Pharmaceuticals shares in Q1 2026, an estimated $97K.
  • Vertex Pharmaceuticals made up 0.03% of Angeles Wealth Management's portfolio in Q1 2026, its #198 holding.
  • Angeles Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Angeles Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.